

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

FAX TRANSMISSION

DATE: March 16, 2009

PTO IDENTIFIER: Application Number 10/081,736
Patent Number

Inventor: Fallon et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: ROPES & GRAY LLP

Hannah Rhys Koyfman, Ph.D.

PHONE: (617) 951-7613

Attorney Dkt. #: BURF-P02-006

PAGES (Including Cover Sheet): 25

CONTENTS:

- Fee Transmittal (1 page)
- Processing Fee Transmittal (1 page)
- Petition to Correct Inventorship (2 pages)
- Statement 1.48(a) of Inventor Alison Amenta (1 page)
- Statement 1.48(a) of Inventor Mary Lynn Mercado (1 page)
- Statement 1.48(a) of Inventor Hiroki Hagiwara (1 page)
- Statement 1.48(b) of Inventor Raymond Ferri (1 page)
- Written Consent of Assignee (1 page)
- Statement 3.73 b (1 page)
- Copy of Assignment for added inventors (4 pages)
- Supplemental Declaration (9 pages)
- Charge \$130.00 to deposit account 18-1945
- Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7613 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP

One International Place, Boston, Massachusetts 02110
Telephone: (617) 951-7000 Facsimile: (617) 951-7050

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/081,736

Attorney Docket No.: BURF-P02-006

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on March 16, 2009
Date



Signature

Andrea Borden

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fee Transmittal (1 page)
Processing Fee Transmittal (1 page)
Petition to Correct Inventorship (2 pages)
Statement 1.48(a) of Inventor Alison Amenta (1 page)
Statement 1.48(a) of Inventor Mary Lynn Mercado (1 page)
Statement 1.48(a) of Inventor Hiroki Hagiwara (1 page)
Statement 1.48(b) of Inventor Raymond Ferri (1 page)
Written Consent of Assignee (1 page)
Statement 3.73 b (1 page)
Copy of Assignment for added inventors (4 pages)
Supplemental Declaration (9 pages)
Charge \$130.00 to deposit account 18-1945

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

003/025

PTO/SB/17 (10-08)


Approved for use through 06/30/2010. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). Fee Transmittal For FY 2009		Complete If Known	
		Application Number	10/081,736
		Filing Date	February 20, 2002
		First Named Inventor	Justin R. Fallon
		Examiner Name	O. N. Chemyshev
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Art Unit	1649
TOTAL AMOUNT OF PAYMENT (\$)		Attorney Docket No. BURF-P02-006	

METHOD OF PAYMENT (check all that apply)			
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 18-1945	Deposit Account Name: Ropes & Gray LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)			
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee		
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments		

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees Paid (\$)
Utility	330	165	540	270	220	110	
Design	220	110	100	50	140	70	
Plant	220	110	330	165	170	85	
Reissue	330	165	540	270	650	325	
Provisional	220	110	0	0	0	0	
2. EXCESS CLAIM FEES							
Fee Description							
Each claim over 20 (including Reissues) 52 26							
Each independent claim over 3 (including Reissues) 220 110							
Multiple dependent claims 390 195							
Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims			
2	- 51 or HP	<input checked="" type="checkbox"/> x _____	= _____	Fee (\$)	Fee Paid (\$)		
HP = highest number of total claims paid for, if greater than 20.							
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)				
10	- 13 or HP	<input checked="" type="checkbox"/> x _____	= _____				
HP = highest number of independent claims paid for, if greater than 3.							
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$270 (\$135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
- 100 =	/50 =	(round up to a whole number) x		=		Fee Paid (\$)	
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1808 Processing fee, except in provisional applications 130.00							

SUBMITTED BY	
Signature	
Name (Print/Type)	Hannah Rhys Koyfman, Ph.D.
Registration No. (Attorney/Agent)	62,912
Telephone	(617) 951-7613
Date	March 16, 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.	
Dated: 3/16/09	Signature:  (Andrea Borden)

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

004/025

PTO/SB/171 (02-09)

Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROCESSING FEE Under 37 CFR 1.17(i) TRANSMITTAL <small>(Fees are subject to annual revision)</small>	Application Number	10/081,736
	Filing Date	February 20, 2002
	First Named Inventor	Justin R. Fallon
	Art Unit	1649
	Examiner Name	O. N. Chemyshev
	Attorney Docket Number	BURF-P02-006

Enclosed is a paper filed under 37 CFR 1.48 that requires a processing fee (37 CFR 1.17(i)).
 Payment of \$ 130.00 is enclosed.

This form should be included with the above-mentioned paper and faxed or mailed to the Office using the appropriate Mail Stop, if applicable. For transmittal of petition fees under 37 CFR 1.17(f), (g) or (h), see form PTO/SB/17p.

Payment of Fees (small entity amounts are NOT available for the processing fees)

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 18-1945 :

processing fee under 37 CFR 1.17(i) any deficiency of fees and credit of any overpayments


Check in the amount of \$ _____ is enclosed.

Payment by credit card (Form PTO-2038 or equivalent enclosed). Do not provide credit card information on this form.

Processing Fees under 37 CFR 1.17(i): Fee \$130 **Fee Code 1808 for all,**
Except for §1.221 papers (Fee Code 1803)

For papers filed under:

§ 1.28(c)(3) – for processing a non-itemized fee deficiency based on an error in small entity status.
 § 1.41 – for supplying the name or names of the inventor or inventors after the filing date without an oath or declaration as prescribed by §1.63, except in provisional applications.
 § 1.48 – for correcting inventorship, except in provisional applications.
 § 1.52(d) – for processing a nonprovisional application filed with a specification in a language other than English.
 § 1.53(b)(3) – to convert a provisional application filed under § 1.53(c) into a nonprovisional application under §1.53(b).
 § 1.55 – for entry of late priority papers.
 § 1.71(g)(2) – to enter an amendment to the specification for purposes of 35 U.S.C. 103(c)(2) if not filed within the cited time periods
 § 1.99(e) – for processing a belated submission under § 1.99.
 § 1.103(b) – for requesting limited suspension of action, continued prosecution application (§ 1.53(d)).
 § 1.103(c) – for requesting limited suspension of action, request for continued examination (§ 1.114).
 § 1.103(d) – for requesting deferred examination of an application.
 § 1.217 – for processing a redacted copy of a paper submitted in the file of an application in which a redacted copy was submitted for the patent application publication.
 § 1.221 – for requesting voluntary publication or republication of an application. Fee Code 1803
 § 1.291(c)(5) – for processing a second or subsequent protest by the same real party in interest.
 § 1.497(d) – for filing an oath or declaration pursuant to 35 U.S.C. 371(c)(4) naming an inventive entity different from the inventive entity set forth in the international stage.
 § 3.81 – for a patent to issue assignee, assignment submitted after payment of the issue fee.



March 16, 2009

Date

Hannah Rhys Koyfman, Ph.D.

62,912

Typed or printed name

Registration No., if applicable

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 3/16/09Signature: Andrea Borden (Andrea Borden)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 3/16/09 Signature: andrea borden
(Andrea Borden)

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE

Examiner: O. N. Chernyshev

PETITION UNDER 37 C.F.R. 1.48(a) TO CORRECT INVENTORSHIP

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully request that Alison Amenta, Mary Lynn Mercado and Kiroki Hagiwara be added as inventors and Raymond Ferri be deleted as an inventor of the above-identified application.

REMARKS

This petition is submitted in accordance with 37 C.F.R. 1.48(a) and 1.48(b) to convert the above-identified application from an application of Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, and Raymond Ferri to an application of Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado and Kiroki Hagiwara. These eight individuals are the actual inventors of the invention currently being claimed.

03/17/2009 VBUI11 00000086 181945 10081736
01 FC:1464 130.00 DA

11679867_1.DOC

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

Application No.: 10/081,736

Docket No.: BURF-P02-006

ATTACHMENTS

Accompanying this petition are:


- (a) Statements by the added inventors, Alison Amenta, Mary Lynn Mercado and Kiroki Hagiwara, establishing that the error occurred without deceptive intent,
- (b) Statement by the deleted inventor, Raymond Ferri, establishing that the error occurred without deceptive intent,
- (c) a statement of the assignee establishing consent,
- (d) a Statement Under 37 CFR 3.73(b) with copies of assignments from the added inventors (to be submitted for recordation separately), and
- (e) an executed Supplementary Declaration for Patent Application.

CONCLUSION

Applicants request that the petition fee in the amount of \$130.00 be charged to Deposit Account No. 18-1945 under Order No. BURF-P02-006, from which the undersigned is authorized to draw. Please charge any other fees and credit any overpayment to Deposition Account No. 18-1945.

Dated: March 16, 2009

Respectfully submitted,

By 
Hannah Rhys Koyfman, Ph.D.
Registration No.: 62,912
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 3/16/09 Signature: Andrea Borden
Andrea Borden

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: **BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE**

Examiner: Chernyshev, Olga N.

STATEMENT OF INVENTOR UNDER 37 C.F.R. 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

1. I, Alison Amenta, was inadvertently omitted as an inventor in the above-identified application, hereinafter called the "referenced application."

2. The referenced application was filed as an application of Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, and Raymond Ferri.

3. The inadvertent omission of my name as an inventor occurred without any deceptive intent on my part.

The undersigned declares further that all statements made herein of his own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Date 2/24/09

Alison Amenta

Alison Amenta

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-6300, on the date shown below.

Dated: 3/16/09 Signature: Andrea Border
Andrea Border

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE

Examiner: Chemyshov, Olga N.

STATEMENT OF INVENTOR UNDER 37 C.F.R. 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


1. I, Mary Lynn Mercado, was inadvertently omitted as an inventor in the above-identified application, hereinafter called the "referenced application."

2. The referenced application was filed as an application of Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, and Raymond Ferri.

3. The inadvertent omission of my name as an inventor occurred without any deceptive intent on my part.

The undersigned declares further that all statements made herein of his own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 02/26/09


Mary Lynn Mercado

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-6300, on the date shown below.

Dated: 3/16/09 Signature: Andrea Borden
(Andrea Borden)

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: **BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE**

Examiner: Chernyshev, Olga N.

STATEMENT OF INVENTOR UNDER 37 C.F.R. 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

1. I, Hiroki Hagiwara, was inadvertently omitted as an inventor in the above-identified application, hereinafter called the "referenced application."

2. The referenced application was filed as an application of Justin R. Fallon, Beth McKechnie, Michael Rafi, Hilliary Creely, Mark A. Bowe, and Raymond Ferri.

3. The inadvertent omission of my name as an inventor occurred without any deceptive intent on my part.

The undersigned declares further that all statements made herein of his own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Date 24 February 2009

Hiroki Hagiwara

Hiroki Hagiwara

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-6300, on the date shown below.

Date: 3/16/09 Signature: Andrea Borden
Andrea Borden

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: **BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE**

Examiner: Chernyshev, Olga N.

STATEMENT OF INVENTOR UNDER 37 C.F.R. 1.48(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

1. I, Raymond Ferri, was inadvertently named as an inventor in the above-identified application, hereinafter called the "referenced application."
2. The referenced application was filed as an application of Justin R. Fallon, Beth McKechnie, Michael Rafii, Hillary Creely, Mark A. Bowe, and Raymond Ferri.
3. The inadvertent addition of my name as an inventor occurred without any deceptive intent on my part.

The undersigned declares further that all statements made herein of his own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Date 2/24/09

Raymond Ferri
Raymond Ferri

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (703) 273-6300, on the date shown below.

Dated: 3/16/09 Signature: Andrea Ponda
Andrea Ponda

Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Fallon et al.

Application No.: 10/081,736

Confirmation No.: 2816

Filed: February 20, 2002

Art Unit: 1649

For: BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE

Examiner: Chernyshev, Olga N.

WRITTEN CONSENT OF ASSIGNEE IN CORRECTION OF
INVENTORSHIP UNDER 37 C.F.R. 1.48(A)(5)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Brown University Research Foundation, is the Assignee of the entire right, title and interest in the above-referenced patent application and hereby consents to the addition of Alison Amenta, Mary Lynn Mercado, and Hiroki Hagiwara and the deletion of Raymond Ferri as inventors in the above-referenced application.

A Statement under 37 C.F.R. 3.73(b) is being filed concurrently with this written consent.

Dated: March 11, 2009

Respectfully submitted,

Brown University Research Foundation

By Clyde L. Bryant

Name C L

Title Vice President for Research

Date March 11, 2009

Approved as to Form

James T. Green
Associate Counsel
Office of the General Counsel
Date: 03/05/09

RECEIVED
CENTRAL FAX CENTER
MAR. 16 2009

PTO/SB/96 (01-08)

Approved for use through 04/02/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Justin R. Fallon, Beth McKechnie, Michael Rafil, Hillary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, and Hiroki Hagihara

Application No./Patent No.: 10/081,736 Filed/Issue Date: February 20, 2002

Entitled: BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE

Brown University Research Foundation, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.

(The extent (by percentage) of its ownership interest is _____ %)
in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012813 Frame 0407, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as follows:


1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Clyde L. Bryant
Printed or Typed Name

Vice President for Research
Title

March 11, 2009

(401) 863-7408

Telephone Number

RECEIVED
CENTRAL FAX CENTER
MAR 16 2009

BURF-P02-006

ASSIGNMENT

WHEREAS, We, Alison Amenta, Mary Lynn Mercado, and Hiroki Hagiwara, have invented a certain improvement in BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE described in an application for Letters Patent of the United States, the specification of which:

[X] was filed on February 20, 2002 as Application No. 10/081,736

WHEREAS, Brown University Research Foundation, (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the Rhode Island, having principal offices at 42 Charlesfield Street, Providence, Rhode Island 02912 desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with our entire right, title and interest in and to said application and such Letters Patent as may issue thereon, and any reissue, continuation, divisional and foreign counterparts thereof; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution,

BURF-P02-006

reissue, divisional or continuation applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

Inventor Alison Amenta Date: 2/24/09
Alison Amenta

Address 225 Glenwood Ave
Pawtucket RI 02860

Witness _____ Date: _____
Address _____

Inventor _____ Date: _____
Mary Lynn Mercado
Address _____

Witness _____ Date: _____
Address _____

BURF-P02-006

reissue, divisional or continuation applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

Inventor _____ Date: _____
Alison Amenta

Address _____

Witness _____ Date: _____
Address _____

Inventor Mary Lynn Mercado Date: 2/26/09
Mary Lynn Mercado
Address 220 Garden Place
Robbinsville, NJ 08691

Witness XIAOTIAN GONG Date: 2/26/09
Address 2 Elsie Dr.
Plainsboro, NJ 08536

BURF-P02-006

Inventor Hiroki Hagiwara Date: 24 February 2009
Hiroki Hagiwara

Address Hakusan 1-32-8-1201 Bunkyo-ku
Tokyo 113-0001 Japan

Witness Heiko Hagiwara Date: 24 Feb. 2009

Address Hakusan 1-32-8-1201 Bunkyo-ku
Tokyo 113-0001 Japan